Hasil Pencarian - Bindu Murthy

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2

    First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2 oleh Ian M. Catlett, Urvi Aras, Lars Hansen, Yali Liu, Di Bei, Ihab G. Girgis, Bindu Murthy

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus

    LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2... oleh Bindu Murthy, Qihong Zhao, Takafumi Ide, Manoj Chiney, Huynh Yen Thanh Bach, Vineet Goti, Coburn Hobar, Urvi Aras

    Diterbitkan 2023-07-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

    Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects oleh Shan Jing, Yang Lin, Randy Dockens, David Marchisin, Bing He, Ihab G. Girgis, Anjaneya Chimalakonda, Bindu Murthy, Urvi Aras

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

    Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder oleh Samira J. Merali, Wonkyung Byon, Yogesh T. Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants

    Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants oleh Vidya Perera, Grigor Abelian, Joseph Luettgen, Ronald Aronson, Danshi Li, Zhaoqing Wang, Liping Zhang, Susan Lubin, Samira Merali, Bindu Murthy

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor

    Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor oleh Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J. Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants

    Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants oleh Vidya Perera, Zhaoqing Wang, Susan Lubin, Takayo Ueno, Tomomi Shiozaki, Wei Chen, Xiaohui Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: